It's the pathway that is the problem. Too many changes, too many promises.
That PRV would have been the way to go.
Pricing of drugs in America, will have a big influence now, A whole new pathway, must be addressed.
Should have stuck to Alzheimer’s, and Fx.
Ann: ACW Science Forum today - Preparing for commercialization, page-46
Add to My Watchlist
What is My Watchlist?
